GlycosBio

GlycosBio is a private, preclinical-stage biotech firm leveraging its proprietary lipid engineering platform to create Activated Oil Systems for enhanced drug delivery and microbiome modulation. Founded in 2007 and operating from the Texas Medical Center, the company follows an R&D and IP licensing business model, collaborating with clients to validate and commercialize technologies. Its pipeline includes clinical programs targeting atopic dermatitis, oral health (S. mutans), and pharyngitis, aiming to provide alternatives to antibiotics and broad-spectrum treatments.

Proprietary lipid engineering and enzymology platform used to create a library of 'Activated Oil Systems' (AOS). These engineered lipids enhance bioavailability, enable targeted delivery, and selectively modulate microbiomes (skin, gut, oral, pulmonary) by targeting pathogens while sparing commensal bacteria.

GlycosBio competes in the crowded fields of advanced drug delivery and microbiome therapeutics. Key competitors include other lipid nanoparticle (LNP) and bioavailability enhancement specialists (e.g., Evonik, Ascendia Pharma) as well as numerous microbiome-focused biotechs (e.g., Vedanta Biosciences, Seres Therapeutics) and large CPG/pharma companies developing microbiome-modifying products. Its differentiation lies in the claimed selectivity of its Activated Oils against pathogens.